Haematologica 2003 - Supplements
Haematologica 2003 - Supplements
Haematologica 2003 - Supplements
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
200<br />
Presentation and outcome of multiple myeloma in<br />
elderly patients: A prospective single center study<br />
Rodon Philippe (1), Giraudeau Bruno (2), Estepa Laurence<br />
(1), Yvon Patrice (1), Akpo-Avallo Jacques (1), Friocourt<br />
Patrick (1)<br />
(1) Unité d`Hématologie, Département de Médecine Interne,<br />
Centre Hospitalier, Blois, France(2) Centre d`Investigation<br />
Clinique, Faculté de Médecine, Tours, France<br />
Few data exist concerning multiple myeloma (MM) in elderly<br />
patients (pts). We reported a multicenter retrospective study<br />
including pts with MM aged 75 years or more at diagnosis<br />
(Rodon et al, Eur J Haematol 2001; 66: 11-17). Median survival<br />
was 22 months. Age ≥85 years, Performance Status (PS) ECOG<br />
≥2 and creatinine level ≥120 mcmol/l were identified as<br />
independent prognostic factors. However, inclusion bias were<br />
possible.<br />
In order to confirm these results, we analyzed survival and<br />
prognostic factors of all consecutive elderly pts with MM<br />
included in a prospective database in a single center from January<br />
1985 to December 2002. One hundred and three pts were<br />
included (M: 51, F: 52). Median age at diagnosis was 81 years<br />
(range 75-97). Twenty six pts were 85 years or older. According<br />
to the Durie and Salmon (DS) staging, 26 pts had stage I, 23 pts<br />
stage II and 53 pts stage III MM. Immunochemical subtype was<br />
IgG in 58 pts, IgA in 31 pts, light chain in 11 pts, other in 3 pts.<br />
Light chain was kappa in 62 pts, lambda in 40 pts, absent in 1 pt.<br />
Forty five significant comorbid diseases were recorded<br />
(cardiovascular 16, neurological 9, 2nd malignancy 8, other 12)<br />
in 41 pts. Infection at diagnosis was found in 23 pts. Twenty<br />
seven pts remained untreated [asymptomatic DS stage I: 18 pts,<br />
stage II-III: 9 pts (heavy comorbidity: 3, poor condition: 3, other:<br />
3)]. In 76 treated pts, initial treatment was a combination of an<br />
alkylating agent and corticosteroids in 69 pts, other in 7 pts.<br />
Response was defined as a reduction ≥25% in M spike level.<br />
Forty five pts were responders, 10 pts were non responders, early<br />
death (ED) (